Advertisement

Drugs

, Volume 74, Issue 16, pp 1973–1981 | Cite as

Pembrolizumab: First Global Approval

  • Raewyn M. Poole
R&D Insight Report

Abstract

Pembrolizumab [Keytruda® (US)], a humanized monoclonal antibody against the programmed death receptor-1 (PD-1) protein, has been developed by Merck & Co for the treatment of cancer. Pembrolizumab has received its first global approval for the treatment of advanced, unresectable or metastatic malignant melanoma in the US, for use in patients with disease progression after prior treatment with ipilimumab and, for BRAF V600 mutation-positive patients, a BRAF inhibitor. It is the first anti-PD-1 therapy to receive regulatory approval in the US, and is currently under regulatory review in the EU. This article summarizes the milestones in the development of pembrolizumab leading to this first approval for the treatment of malignant melanoma.

Keywords

Melanoma Objective Response Rate Ipilimumab Axitinib Crizotinib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ascierto PA, Kalos M, Schaer DA, et al. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res. 2013;19(5):1009–20.CrossRefGoogle Scholar
  2. 2.
    Mamalis A, Garcha M, Jagdeo J. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Archiv Dermatol Res (Archiv fur Dermatologische Forschung). 2014;306(6):511–9.CrossRefGoogle Scholar
  3. 3.
    Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–17.CrossRefGoogle Scholar
  4. 4.
    Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for melanoma. Am J Clin Dermatol. 2014;15(4):323–37.CrossRefGoogle Scholar
  5. 5.
    Tang PA, Heng DYC. Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer. Curr Oncol Rep. 2013;15(2):98–104.CrossRefGoogle Scholar
  6. 6.
    Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control. 2014;21(1):80–9.CrossRefGoogle Scholar
  7. 7.
    Johnson DB, Rioth MJ, Horn L. Immune Checkpoint Inhibitors in NSCLC. Curr Treat Options Oncol. 2014;. doi: 10.1007/s11864-014-0305-5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Merck & Co. KEYTRUDA (Pembrolizumab) Prescribing Information. 2014. http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed 17 Sept 2014.
  9. 9.
    U.S. Food and Drug Administration. FDA approves Keytruda for advanced melanoma [media release]. 4 Sept 2014. www.fda.gov.
  10. 10.
    Merck & Co. Merck announces breakthrough therapy designation for lambrolizumab an investigational antibody therapy for advanced melanoma [media release]. 24 April 2013. www.merck.com.
  11. 11.
    Merck & Co. MSDs investigational anti-PD-1 antibody, pembrolizumab, under regulatory review in europe for the treatment of advanced melanoma [media release]. 30 June 2014. www.merck.com.
  12. 12.
    Merck & Co. Merck announces FDA acceptance for review of MK-3475 biologics license application for advanced melanoma [media release]. 6 May 2014. www.merck.com.
  13. 13.
    Merck & Co. Merck initiates rolling submission of U.S. biologics license application for MK-3475, an investigational anti-PD-1 immunotherapy, in patients with advanced melanoma [media release]. 12 Jan 2014. www.merck.com.
  14. 14.
    Incyte Corporation. Incyte announces clinical trial collaboration with merck to evaluate combination of two novel immunotherapies [media release]. 5 Feb 2014. www.incyte.com.
  15. 15.
    Merck & Co. Merck enters strategic collaborations with Amgen, Incyte and Pfizer to evaluate novel combination anti-cancer regimens with MK-3475 [media release]. 5 Feb 2014. www.merck.com.
  16. 16.
    Incyte Corporation. Incyte reports 2014 first-quarter financial results and updates shareholders on key clinical programs [media release]. 1 May 2014. www.incyte.com.
  17. 17.
    Advaxis. Advaxis and Merck form collaboration to evaluate investigational combination of two novel immunotherapy candidates for advanced prostate cancer [media release]. 25 Aug 2014. www.advaxis.com.
  18. 18.
    Pfizer. Pfizer and Merck to collaborate on study evaluating novel anti-cancer combination regimen [media release]. 26 Aug 2014. www.pfizer.com.
  19. 19.
    Pfizer. Pfizer and Merck to collaborate on innovative anti-cancer combination studies. [media release]. 5 Feb 2014. www.pfizer.com.
  20. 20.
    Amgen, Merck. Amgen and Merck announce collaboration to evaluate investigational combination treatment for advanced melanoma. [media release]. 5 Feb 2014. www.amgen.com.
  21. 21.
    Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44.CrossRefGoogle Scholar
  22. 22.
    Kefford R, Ribas A, Hamid O, et al. Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstract no. 3005]. In: 50th Annual Meeting of the American Society of Clinical Oncology: 2014; Chicago, IL.Google Scholar
  23. 23.
    Hamid O, Robert C, Ribas A, et al. Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL) [abstract no. 3000]. In: 50th Annual Meeting of the American Society of Clinical Oncology: 2014; Chicago, IL.Google Scholar
  24. 24.
    Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody mk-3475 in 411 patients (PTS) with melanoma (MEL). J Clin Oncol Conf. 2014;32(18 Suppl 1):LBA9000.CrossRefGoogle Scholar
  25. 25.
    Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol Conf. 2014;32(15 Suppl 1):3015.Google Scholar
  26. 26.
    Hodi FS, Ribas A, Daud A, et al. Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol Conf. 2014;32(15 Suppl 1):3006.Google Scholar
  27. 27.
    Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) [abstract no. 8007]. In: 50th Annual Meeting of the American Society of Clinical Oncology: 2014; Chicago, IL.Google Scholar
  28. 28.
    Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract no. 8020]. In: 50th Annual Meeting of the American Society of Clinical Oncology: 2014; Chicago, IL.Google Scholar
  29. 29.
    Merck Sharp & Dohme Corp. Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) [ClinicalTrials.gov Identifier: NCT01866319]; US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ct2/show/NCT01866319?term=pembrolizumab&rank=11. Accessed 17 Sept 2014.
  30. 30.
    Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002) [ClinicalTrials.gov Identifier: NCT01704287] US National Institutes of Health, ClinicalTrials.gov. 2012. http://clinicaltrials.gov/ct2/show/NCT01704287?term=pembrolizumab&rank=9. Accessed 17 Sept 2014.
  31. 31.
    Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) [ClinicalTrials.gov Identifier: NCT01295827] US National Institutes of Health, ClinicalTrials.gov. 2011. http://clinicaltrials.gov/ct2/show/NCT01295827?term=pembrolizumab&rank=2. Accessed 17 Sept 2014.
  32. 32.
    Merck Sharp & Dohme Corp. Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) [ClinicalTrials.gov Identifier: NCT01905657] US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ct2/show/NCT01905657?term=pembrolizumab&rank=8. Accessed 17 Sept 2014.
  33. 33.
    Herbst RS, Gurpide A, Surmont V, et al. A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer [abstract no. TPS8124]. In: 50th Annual Meeting of the American Society of Clinical Oncology: 2014; Chicago, IL.Google Scholar
  34. 34.
    Merck Sharp & Dohme Corp. A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021) [ClinicalTrials.gov Identifier: NCT02039674] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT02039674?term=pembrolizumab&rank=7. Accessed 17 Sept 2014.
  35. 35.
    Merck Sharp & Dohme Corp. A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022) [ClinicalTrials.gov Identifier: NCT02130466] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT02130466?term=pembrolizumab&rank=16. Accessed 17 Sept 2014.
  36. 36.
    Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) [ClinicalTrials.gov Identifier: NCT02142738] US National Intitutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT02142738?term=pembrolizumab&rank=4. Accessed 17 Sept 2014.
  37. 37.
    Merck Sharp & Dohme Corp. Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) [ClinicalTrials.gov Identifier: NCT02007070] US National Institutes of Health, ClinicalTrials.gov. 2013. http://clinicaltrials.gov/ct2/show/NCT02007070?term=pembrolizumab&rank=17. Accessed 17 Sept 2014.
  38. 38.
    Merck Sharp & Dohme Corp. Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab + Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) [ClinicalTrials.gov identifier NCT02220894]; US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT02089685?term=pembrolizumab&rank=10. Accessed 17 Sept 2014.
  39. 39.
    Incyte Corporation. A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) [ClinicalTrials.gov Identifier: NCT02178722] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT02178722?term=NCT02178722&rank=1. Accessed 18 Sept 2014.
  40. 40.
    Yale University. MK-3475 in Melanoma and NSCLC Patients With Brain Metastases [ClinicalTrials.gov Identifier: NCT02085070] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT02085070?term=mk-3475&rank=4. Accessed 18 Sept 2014.
  41. 41.
    Merck Sharp & Dohme Corp. Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) [ClinicalTrials.gov Identifier: NCT02220894] US National Institutes of Health, ClinicalTrials.gov. 2014. http://clinicaltrials.gov/ct2/show/NCT02220894?term=pembrolizumab&rank=3. Accessed 17 Sept 2014.

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations